EXACT Sciences Corporation Stock News

MADISON, Wis. , June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate

Tesla, DraftKings, and Exact Sciences all saw their shares tank in 2022. But this year they have been some of the ARK Innovation ETF's best performers.

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public o

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

The Cathie Wood style of investing has certainly fallen out of favor over the last year or two. While some growth stocks have rebounded nicely, many Cathie Wood stocks have been crushed.

Exact Sciences (NASDAQ:EXAS) Corporation earned a price target raise from Canaccord Genuity (TSX:CF, LSE:CF) after the molecular diagnostics company specializing in the detection of early-stage cance

Diagnostic and cancer test products provider Exact Sciences Corp. NASDAQ: EXAS saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer detecti

Medicine is not always simple. A drug that cures one patient can easily kill another, based on anything from their weight to their genes to anything else.

Exact Sciences has been hit hard by the challenging economy over the past year or so. Recent strong results have investors thinking the selling has simply gone too far.

Exact Sciences reported first-quarter earnings last Tuesday. Thanks to multiple positive developments, investors bid up the biotech's shares this week.

Several analysts upgraded their price targets for Exact Sciences. The company saw revenue rise by 24% year over year.

Exact Sciences (NASDAQ: EXAS ) reported results for the first quarter of 2023. Exact Sciences reported a loss per share of 42 cents.

Exact Sciences crushed first-quarter expectations late Tuesday and raised its outlook for the year. The news is likely to stoke EXAS stock.

Finding stocks that will outperform the market is a daunting task in any market. It's challenging when every sector in the S&P 500 is getting hammered.